Figure_1.tif (1.16 MB)
Download file

Overview of the RAE workflow.

Download (0 kB)
posted on 11.09.2008, 00:30 by Barry S. Taylor, Jordi Barretina, Nicholas D. Socci, Penelope DeCarolis, Marc Ladanyi, Matthew Meyerson, Samuel Singer, Chris Sander

Input is a set of patients; tumor DNA, (un) matched non-tumor DNA, and an unrelated reference normal cohort. Tumor and non-tumor samples are quantified, normalized, and subject to quality control. In the assessment phase, individual samples are segmented and a multi-component model is parameterized for each; this produces a detector for single-copy gain, amplification, hemizygous loss, and homozygous deletion. Across all tumors, a unified breakpoint profile (UBP) is derived from the ensemble of segmentation breakpoints, and each region is scored for gain and loss. A background model of random aberrations is constructed with supplemental cleavage and permutation of genomic regions, and p-values are assigned and corrected for multiple hypothesis testing. In the output phase, RAE determines genomic boundaries for regions of interest (ROI), controls for germline and population copy-number variation, and reports statistically significant alterations.


Usage metrics

Read the peer-reviewed publication